Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...318319320321322323324325326327328...10671068»
  • ||||||||||  dexamethasone / Generic mfg., fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
    SAFETY AND EFFICACY OF BCMA-CAR-T IMMUNE CELLS DERIVED FROM CORD BLOOD IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA () -  May 13, 2022 - Abstract #EHA2022EHA_2092;    
    2-3 days after being administered the lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine, patients received CAR-T cells infusion...No patients received dexamethasone to relieve symptoms...Conclusion BCMA-CAR-T cells manufactured from CB show a promising safety profile and certain clinical efficacy for R/RMM patients who are not eligible for autologous CAR-T cells therapy. We also found allogeneic CAR-T cells manufactured from CB could prepare patients for later subsequent autologous CAR-T therapy.
  • ||||||||||  carfilzomib / Generic mfg.
    CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY () -  May 13, 2022 - Abstract #EHA2022EHA_2072;    
    K was used in a double regimen with dexamethasone (Kd) in 232 patients (45.3%) and in a triple regimen either with an IMID (K-IMID) in 198 (38.7%) patients or with other agents in 82 patients (16%) (K-aCD38 for 35 (6.8%), K-alkylant for 27 (5.3%) and K-venetoclax for 19 (3.7%) patients)...K was combined with len in 144 (28,1%) and with pomalidomide (pom) in 54 (10,5%) patients...K-aCD38 (33/35 with daratumumab) was used in L2 (31.4%), L3/L4 (35.7%) and L5+ (22.9%)...K-alkylant (5/27 with bendamustine, 22/27 cyclophosphamide) and K-venetoclax were used in older patients (71.8y and 70.4y) and in L4 or L5 for >80% of them...Conclusion The EMMY study shows that carfilzomib is used in many combinations in extended real-life settings compared to pivotal clinical trials including older patients, largely-exposed to lenalidomide and at advanced disease. The use of lenalidomide in early stages has led to a shift in the management of RRMM patients with carfilzomib.
  • ||||||||||  Darzalex (daratumumab) / J&J
    WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT) () -  May 13, 2022 - Abstract #EHA2022EHA_2050;    
    391 NDMM patients (age 18-75 years) eligible for ASCT will be enrolled in the phase II part of the study and receive standard of care (SOC) 1.L treatment according to Norwegian national guidelines; four pre-transplant induction and four post-transplant consolidation cycles of bortezomib, lenalidomide and dexamethasone (VRd)...At loss of MRD negativity in arm A or at PD in arm B, second line treatment will be carfilzomib, dexamethasone and daratumumab until progressive disease...In Table 1 baseline characteristics and results are presented. Conclusion Part 1 of the REMNANT study will clarify the overall response rate and depth of response measured by MRD, after SOC Norwegian 1.L treatment Part 2 will determine if treating patients at MRD relapse, when tumor burden is lower, will improve outcome.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY () -  May 13, 2022 - Abstract #EHA2022EHA_2049;    
    Background Standard therapies for newly diagnosed multiple myeloma (NDMM) patient’s ineligible for autologous stem-cell transplantation (ASCT) have been lenalidomide-dexamethasone (Rd), bortezomib-lenalidomide-dexamethasone (VRd) or bortezomib-melphalan-prednisone (VMP)...Isatuximab is an anti-CD38 mAb approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone to treat relapsed/refractory MM, and has also shown clinical responses as combination therapy to treat NDMM (Trudel, 2019)...Isa-VRd is showing encouraging preliminary efficacy in NDMM ineligible for transplant. Enrollment and follow-up is ongoing.
  • ||||||||||  Mozobil (plerixafor) / Sanofi
    ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY () -  May 13, 2022 - Abstract #EHA2022EHA_2030;    
    P=N/A
    Background High-dose melphalan and autologous stem-cell transplant (ASCT) are pillars for the upfront treatment of ASCT-eligible newly diagnosed multiple myeloma (ND)MM patients (pts) or as salvage strategy at relapse...Results 301 NDMM pts were enrolled and analyzed; 72% received induction with bortezomib-thalidomide-dexamethasone, 9% a lenalidomide (Len)-based and 3% a daratumumab (Dara)-based regimen...Predictive factors for PLX use were advanced disease stage, high BM plasmacytosis, low ANC values before mobilization and the use of Len/Dara during induction. Preemptive PLX in pts with ≥1 risk factors should be investigated to further reduce the risk of mobilization failure.
  • ||||||||||  Ninlaro (ixazomib) / Takeda, Darzalex Faspro (daratumumab/hyaluronidase) / J&J
    IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM). () -  May 13, 2022 - Abstract #EHA2022EHA_2028;    
    P2
    Methods Ixa-Dara naïve RRMM patients received oral Ixazomib (4 mg: days 1, 8, 15), IV Daratumumab (16 mg/kg; days 1, 8, 15, 22, cycles 1-2; days 1, 15, cycles 3-6; days 1, cycles 7+) and IV Methylprednisolone before Daratumumab (100 mg at day 1, 8, cycle 1 and then 60 mg)...Thirty-three patients (60%) were previously exposed to bortezomib, 37 (67%) were previously exposed to lenalidomide (Len) and 20 (36 %) were refractory to Len...Conclusion In this elderly frail population Ixa-Dara is a feasible combination with favorable efficacy profile even in Len refractory and HR cytogenetic patients. Early toxicity remains a concern in this population eventhough more manageable with Dara SC.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., thalidomide / Generic mfg.
    YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A TUNISIAN SINGLE-CENTER EXPERIENCE () -  May 13, 2022 - Abstract #EHA2022EHA_2011;    
    The RR after supportive care measurements and antimyeloma therapy was 74%, which is slightly lower to what is found in the literature (77%). Thus, early diagnosis and rapid initiation of a triplet Brotezomib based regimen for this high-risk group is essential and improves renal outcomes in RI pts.
  • ||||||||||  dexamethasone / Generic mfg.
    FACTORS ASSOCIATED WITH EARLY RELAPSE IN MYELOMA PATIENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION () -  May 13, 2022 - Abstract #EHA2022EHA_2006;    
    Autologous hematopoietic stem cell transplantation (ASCT) after an induction regimen using combination of immunomodulatory drugs, proteasome inhibitors and dexamethasone is considered the standard treatment of newly diagnosed multiple myeloma in eligible patients...The fact that 43% of our patients have EM disease involvement in diagnosis indicates that this feature may be associated with early relapse. Outcomes of single and tandem ASCT in these patients should be examined in further studies.
  • ||||||||||  Darzalex (daratumumab) / J&J, Ninlaro (ixazomib) / Takeda
    TREATMENT PATHWAYS AT FIRST RELAPSE POST-ASCT IN MULTIPLE MYELOMA: IMPACT OF MAINTENANCE THERAPY ON TREATMENT OPTIONS () -  May 13, 2022 - Abstract #EHA2022EHA_2001;    
    However, most MM patients will relapse post-ASCT and many effective relapse regimens have a lenalidomide backbone (e.g. KRD: carfilzomib, lenalidomide, dexamethasone, DRD: daratumumab-RD, IRD: ixazomib-RD) making choice of regimen at first relapse increasingly difficult in patients progressing during LenM therapy...The most frequently used induction was cyclophosphamide(C), bortezomib(V) and dexamethasone(D) (>60%, VCD)...Regimens included carfilzomib/dexamethasone (KD) n=16 +/- lenalidomide (KRD) n=1, pomalidomide (PD), n=1, ixazomib (ID) n=1, dara (n=3) and dara combinations, including daraVD, n=1, and daraPD, n=1...We have noted significant changes in choice of therapy upon relapse, with carfilzomib prescription rates increasing and lenalidomide-based regimen use decreasing. Our real world data provides direct insight into the effect of widespread LenM therapy on choice of agent upon relapse and highlights the need for consensus treatment guidelines to reflect this evolution in treatment for MM patients.
  • ||||||||||  Darzalex (daratumumab) / J&J
    UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC). () -  May 13, 2022 - Abstract #EHA2022EHA_1990;    
    Pts receiving 1 st line were 100% (61), 90,2% of the pts received bortezomib (V) - based induction, of them 29% (n=16) were treated with alkylating agents, 49,1% (n=27) received IMIDs and 18,2% (n=10) V with dexamethasone (d), plus two of these pts received regimens composed of 3xVCd + 3xVPd and the other dara-VRd...2 nd line, 32 pts (52,5%), (n=3) VTD-PACE, (n=6) daratumumab (n=1 alone, 3 R, 1 V, 1 K), (n=1) Kdexa, (n=1) Pocydex and (n=9) V plus 3 IMIDs, 2 alkylating, 2 P or 2 alone and (n=12) IMIDs and alkylatings in combination...In the last lines, the use of triplets with pomalidomide, karfilzomib or intensive chemotherapy prevail...As treatment lines progress, therapeutic combinations are more heterogeneous and less concordant. A further longer follow-up and higher HRC NDMM pts`s recruitment will be necessary to clarify the response to tto regimens based on individual cytogenetic groups.
  • ||||||||||  CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH PLASMA CELL LEUKEMIA (PCL): A SINGLE-CENTER STUDY FROM TUNISIA () -  May 13, 2022 - Abstract #EHA2022EHA_1983;    
    Conclusion As reported internationally, our study showed that patients with PCL were younger than myeloma patients, and presented with more aggressive clinical and laboratory features at diagnosis especially more bone lesions than classically described, and a high frequency of hypercalcemia. Besides, it indicated that even after the use of novel drugs, response to treatment is poor and PCL still has a poor prognosis.
  • ||||||||||  Darzalex (daratumumab) / J&J
    REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S. () -  May 13, 2022 - Abstract #EHA2022EHA_1981;    
    Real-world dosing frequency of daratumumab over 36 months of follow-up (N=2125) Abbreviations: RWD, real world data; SD, standard deviation; PI, prescribing information for DRd and DPd as approved label Conclusion Patients initiating DARA remain on the therapy for a median of 16.6 months with one-sixth continuing DARA beyond 3 years. The dosing frequency observed in the real-world was consistent with the approved label.
  • ||||||||||  MULTIPLE MYELOMA IN THE ELDERLY: A MONOCENTRIC EXPERIENCE () -  May 13, 2022 - Abstract #EHA2022EHA_1975;    
    The combination of bortezomib-lenalidomide-dexamethasone for elderly patients may improve our results. In addition, structured frailty assessment is required in order to devise individualized treatment plan able to improve the clinical outcomes and the Quality of life.
  • ||||||||||  dexamethasone / Generic mfg., pomalidomide / Generic mfg.
    DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE () -  May 13, 2022 - Abstract #EHA2022EHA_1973;    
    Nine patients have surprisingly achieved a notable response (3 VGPR, 4 PR, 2 MR) after failure of novel agents (i.e. Carfilzomib, Daratumumab and Pomalidomide). Conclusion Pomalidomide-dexamethasone has shown significant efficacy and a very good compliance, thanks to oral administration, in a particularly severe setting of heavily pretreated patients, relapsed and refractory to all available therapeutic resources, also after failure of novel agents.